Meeting to feature latest clinical findings on GA Depot and showcase commitment to improving care for people living with multiple...
-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE...
GOTHENBURG, SWEDEN / ACCESSWIRE / October 10, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company...
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of...
The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire...
- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the...
VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that...
Nomination of novel drug target based on insights generated through application of Verily’s Immune Profiler platform and Sosei Heptares’ GPCR-focused...
Bellamy Young is Moving Past Stigma as She Speaks Candidly about Her Father's Struggle with Chronic Liver Disease/Cirrhosis and Resulting...
Dr. Mario Capecchi, Nobel Laureate at University of Utah, to Deliver Keynote on Research to Understand Symptoms Prevalent in Individuals...
NME is a progressive, typically fatal autoimmune disease characterized by brain inflammation, that has no disease-modifying treatment options availableSAN DIEGO...
STOCKHOLM, SWEDEN / ACCESSWIRE / October 3, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a...
LAVAL, QC / ACCESSWIRE / September 29, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of...
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...
Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential...
-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be...
– Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for...
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment...
SACRAMENTO, CA / ACCESSWIRE / September 21, 2023 / Consumer health advocates and providers lauded California Physical Therapy Association sponsored...